Orthofix International N.V.
10/24/12

Orthofix International Announces Launch of VersaShield™ Amniotic Membrane

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today the introduction of VersaShield™, a naturally physiologic wound covering for use in both spinal and orthopedic applications. This amniotic allograft tissue form is processed by The Musculoskeletal Transplant Foundation, or MTF.

"We are very excited to be showcasing our second biologic tissue form from MTF this week at the 2012 North American Spine Society meeting," said President and Chief Executive Officer Robert Vaters. "This launch further demonstrates our commitment to expand our biologic offering, which goes hand in hand with our Value Proposition of providing surgeons a breadth of hardware, biologic, and stimulation solutions. In further collaboration with MTF, we are also excited about our launch next year of Trinity® Elite™, which is the next generation our highly successful Trinity Evolution®."

Bruce Stroever, CEO of MTF commented, "For more than a century, doctors have used amniotic tissue for a broad variety of clinical applications in such fields as General Surgery, Dental, Ob/Gyn, Ocular Surgery, Spine and Sports Medicine. This is due to the beneficial anti-inflammatory, anti-adhesive, anti-microbial, and non-immunogenic properties of the tissue graft. MTF is pleased to continue our partnership with Orthofix on the introduction of VersaShield™ amniotic membrane in order to make innovative biologic solutions available to all spine and orthopedic surgeons."

VersaShield™ is an allograft tissue processed from placental tissue recovered from living donors during healthy child births. VersaShield™ can be stored at room temperature and possesses easy handling characteristics. It will be distributed by our spine and orthopedic distribution networks.

About Orthofix:

Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix's products are widely distributed around the world to orthopedic surgeons and patients via Orthofix's sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.

About the Musculoskeletal Transplant Foundation

The Musculoskeletal Transplant Foundation is the nation's largest full service tissue organization dedicated to providing high quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A not-for-profit organization, MTF is a consortium of academic medical institutions and organ and tissue recovery organizations across the country. Since MTF's inception, MTF has maintained an exemplary safety record distributing almost 5 million allografts from nearly 90,000 donors. For more information, please visit MTF's website at www.mtf.org.

Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations and Business Development
markquick@orthofix.com

Source: Orthofix International N.V.

News Provided by Acquire Media